Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499835 | 0.88 | EGFR (0.65) | SMN1; SMN2EGFRERBB3NPC1ALDH1A1 | |
| SCHEMBL29920018 | 0.81 | EGFR (0.58) | SMN1; SMN2EGFRERBB3NPC1ALDH1A1 | |
| SCHEMBL28936534 | 0.81 | EGFR (0.58) | SMN1; SMN2EGFRERBB3NPC1ALDH1A1 | |
| SCHEMBL1938370 | 0.79 | ADORA3 (0.76) | SMN1; SMN2EGFRERBB3NPC1ALDH1A1 | |
| SCHEMBL1706080 | 0.79 | RAB9A (0.55) | JAK2TYK2RAB9A | |
| SCHEMBL18185358 | 0.79 | L3MBTL1 (0.48) | EGFRERBB3NPC1MEN1KMT2A | |
| SCHEMBL8211768 | 0.78 | POLB (0.47) | SMN1; SMN2ALDH1A1ATMMEN1KMT2A | |
| SCHEMBL8803532 | 0.78 | MEN1 (0.44) | SMN1; SMN2EGFRERBB3NPC1MEN1 | |
| SCHEMBL14758708 | 0.78 | KMO (0.64) | SMN1; SMN2EGFRERBB3NPC1ALDH1A1 | |
| SCHEMBL28650577 | 0.77 | JAK2 (0.63) | SMN1; SMN2NPC1ALDH1A1ATMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1155278-A | Arylthio compounds as antibacteral and antiviral agents | WARNER LAMBERT CO (US) | 1997-07-23 | — | — | CN | claimed |
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | disclosed |
| EP-3707151-B1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICALS CO (JP) | 2022-01-05 | — | — | EP | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3707151-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | Takeda Pharmaceutical Company Limited (JP) | 2020-09-16 | — | — | EP | disclosed |
| CN-111566119-A | STING modulator compounds and methods of making and using | 武田药品工业有限公司 | 2020-08-21 | — | — | CN | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
| US-8093246-B2 | potent deoxycytidine kinase inhibitors; O-linked pyrimidin-4-amine-based compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093246-B2 | potent deoxycytidine kinase inhibitors; O-linked pyrimidin-4-amine-based compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-06-19 | — | — | US | disclosed |
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-06-19 | — | — | US | disclosed |
| CN-1155278-A | Arylthio compounds as antibacteral and antiviral agents | WARNER LAMBERT CO (US) | 1997-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | SMN1; SMN2 1969/4885EGFR 1818/4885ERBB3 3787/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | SMN1; SMN2 1969/4885EGFR 1818/4885ERBB3 3787/4885 |
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | SMN1; SMN2 1969/4885EGFR 1818/4885ERBB3 3787/4885 |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | SMN1; SMN2 1969/4885EGFR 1818/4885ERBB3 3787/4885 |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | SMN1; SMN2 4703/4885EGFR 3329/4885ERBB3 3137/4885 |
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | DPYD, DHFR, TYMP | SMN1; SMN2 1519/4885EGFR 697/4885ERBB3 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.